Efficacy of topical latanoprost in the treatment of eyelid vitiligo: A randomized, double‐blind clinical trial study. Issue 1 (26th December 2019)

• Record Type: Journal Article
• Authors: Nowroozpoor Dailami, Kiumars; Hosseini, Azita; Rahmatpour Rokni, Ghasem; Saeedi, Majid; Morteza‐Semnani, Katayoun; Sadeghi, Zeinab; Ghasemzadeh Diva, Seyed M.; Goldust, Mohamad; Lotti, Torello; Vojvodic, Aleksandra; Goren, Andy; Sonthalia, Sidharth; Rathod, Dipali
• Is Part Of: Dermatologic therapy. Volume 33:Issue 1(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-12-26
• Subjects: eyelid patch -- latanoprost -- prostaglandin F2α analogue -- vitiligo; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/dth.13175
• Languages: English
• ISSNs: 1396-0296

Abstract

Abstract: Numerous studies have demonstrated that the pigmentation of iris and around the eyelid is a common side effect of latanoprost, a prostaglandin F2alpha analogue used in the treatment of glaucoma. Hence, the authors decided to study the effectiveness of topical latanoprost on vitiligo patches around the eyelid. In this randomized, double‐blind, clinical trial study, 31 patients with vitiligo vulgaris and focal vitiligo involving the eyelids were evaluated. Patients were randomly divided into two groups. First group received topical latanoprost gel twice daily for 12 weeks, whereas the second group received placebo with the same protocol. To evaluate severity of the disease the VIDA rating system was used. Serial photos of the patches were taken to compare and evaluate the repigmentation percentage of the patches. The patients in both groups had almost similar VIDA score ( p > .05). First group showed improved pigmentation, whereas participants in the second group did not show any improvement in the pigmentation. The group treated with latanoprost showed significant reduction in the symptoms of the disease, whereas those treated with placebo did not show any alteration ( p > .05). No significant complications were observed in either groups. Latanoprost proved effective in treating vitiligo disease involving eyelids.